Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$17.42
$17.42
$14.50
▼
$19.92
$424.04M1.1518,480 shsN/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
$19.81
-0.1%
$14.66
$4.19
▼
$19.86
$1.23B1.341.09 million shs181,835 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.00%0.00%0.00%0.00%+6.28%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
0.00%+0.51%+128.46%+38.19%+190.34%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$17.42
$17.42
$14.50
▼
$19.92
$424.04M1.1518,480 shsN/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
$19.81
-0.1%
$14.66
$4.19
▼
$19.86
$1.23B1.341.09 million shs181,835 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.00%0.00%0.00%0.00%+6.28%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
0.00%+0.51%+128.46%+38.19%+190.34%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
1.00
SellN/AN/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
2.14
Hold$24.0021.18% Upside

Current Analyst Ratings Breakdown

Latest HZD, OXB, SLN, and PRTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/21/2026
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
DowngradeStrong-Buy ➝ Hold
10/21/2026
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
DowngradeBuy ➝ Neutral$75.00 ➝ $20.00
10/19/2026
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
DowngradeBuy ➝ Hold$20.00
10/19/2026
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
DowngradeOutperform ➝ Hold
10/15/2026
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Reiterated RatingSell (D-)
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$4.66M91.01N/AN/A$12.65 per share1.38
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
$615K2,001.56N/AN/A$1.32 per share15.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
-$109.74MN/AN/AN/AN/AN/AN/AN/AN/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-$88.61M-$1.07N/AN/AN/A-8,943.86%-102.72%-43.70%N/A

Latest HZD, OXB, SLN, and PRTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-$0.1129-$0.24-$0.1271-$0.24$0.11 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/AN/AN/AN/AN/A
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/A
6.59
6.59
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
N/A
7.42
7.42

Institutional Ownership

CompanyInstitutional Ownership
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.04%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
98.73%

Insider Ownership

CompanyInsider Ownership
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
5.30%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
3.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
10024.34 million23.05 millionNot Optionable
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
8862.15 million60.29 millionOptionable

Recent News About These Companies

Silence Therapeutics jumps 59% on Merck takeover

New MarketBeat Followers Over Time

Media Sentiment Over Time

PureTech Health stock logo

PureTech Health NASDAQ:PRTC

$17.42 0.00 (0.00%)
As of 11/6/2026

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Silence Therapeutics stock logo

Silence Therapeutics NASDAQ:SLN

$19.80 -0.03 (-0.13%)
As of 02:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.